Cargando…

Tubulin binding potentially clears up Bortezomib and Carfilzomib differential neurotoxic effect

Proteasome inhibitors (PIs) represent the gold standard in the treatment of multiple myeloma. Among PIs, Bortezomib (BTZ) is frequently used as first line therapy, but peripheral neuropathy (PN), occurring approximately in 50% of patients, impairs their life, representing a dose-limiting toxicity. C...

Descripción completa

Detalles Bibliográficos
Autores principales:	Malacrida, A., Semperboni, S., Di Domizio, A., Palmioli, A., Broggi, L., Airoldi, C., Meregalli, C., Cavaletti, G., Nicolini, G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8131610/ https://www.ncbi.nlm.nih.gov/pubmed/34006972 http://dx.doi.org/10.1038/s41598-021-89856-3

Ejemplares similares

Proteomic approach for understanding milder neurotoxicity of Carfilzomib against Bortezomib
por: Karademir, Betul, et al.
Publicado: (2018)

An Overview of Bortezomib-Induced Neurotoxicity
por: Meregalli, Cristina
Publicado: (2015)

Sodium-Calcium Exchanger 2: A Pivotal Role in Oxaliplatin Induced Peripheral Neurotoxicity and Axonal Damage?
por: Ballarini, Elisa, et al.
Publicado: (2022)

Pathogenic role of delta 2 tubulin in bortezomib-induced peripheral neuropathy
por: Pero, Maria Elena, et al.
Publicado: (2021)

Reversal of Bortezomib-Induced Neurotoxicity by Suvecaltamide, a Selective T-Type Ca-Channel Modulator, in Preclinical Models
por: Meregalli, Cristina, et al.
Publicado: (2021)

Higher proteotoxic stress rather than mitochondrial damage is involved in higher neurotoxicity of bortezomib compared to carfilzomib
por: Jannuzzi, Ayse Tarbin, et al.
Publicado: (2020)

Nelfinavir augments proteasome inhibition by bortezomib in myeloma cells and overcomes bortezomib and carfilzomib resistance
por: Kraus, M, et al.
Publicado: (2013)

Susceptibility of different mouse strains to oxaliplatin peripheral neurotoxicity: Phenotypic and genotypic insights
por: Marmiroli, Paola, et al.
Publicado: (2017)

High-dose intravenous immunoglobulins reduce nerve macrophage infiltration and the severity of bortezomib-induced peripheral neurotoxicity in rats
por: Meregalli, Cristina, et al.
Publicado: (2018)

Cannabinoids: an Effective Treatment for Chemotherapy-Induced Peripheral Neurotoxicity?
por: Cavaletti, Guido, et al.
Publicado: (2021)

Role of Mouse Organic Cation Transporter 2 for Nephro- and Peripheral Neurotoxicity Induced by Chemotherapeutic Treatment with Cisplatin
por: Hucke, Anna, et al.
Publicado: (2023)

Paclitaxel, but Not Cisplatin, Affects Satellite Glial Cells in Dorsal Root Ganglia of Rats with Chemotherapy-Induced Peripheral Neurotoxicity
por: Pozzi, Eleonora, et al.
Publicado: (2023)

Anti-leukemic activity of bortezomib and carfilzomib on B-cell precursor ALL cell lines
por: Takahashi, Kazuya, et al.
Publicado: (2017)

Current View in Platinum Drug Mechanisms of Peripheral Neurotoxicity
por: Chiorazzi, Alessia, et al.
Publicado: (2015)

Milder degenerative effects of Carfilzomib vs. Bortezomib in the Drosophila model: a link to clinical adverse events
por: Tsakiri, Eleni N., et al.
Publicado: (2017)

Carfilzomib–dexamethasone vs bortezomib–dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVOR
por: Chng, W-J, et al.
Publicado: (2017)

Bortezomib-Induced Painful Peripheral Neuropathy: An Electrophysiological, Behavioral, Morphological and Mechanistic Study in the Mouse
por: Carozzi, Valentina A., et al.
Publicado: (2013)

Bortezomib Treatment Produces Nocifensive Behavior and Changes in the Expression of TRPV1, CGRP, and Substance P in the Rat DRG, Spinal Cord, and Sciatic Nerve
por: Quartu, M., et al.
Publicado: (2014)

Chemotherapy-Induced Peripheral Neuropathy and Changes in Cytoskeleton
por: Malacrida, Alessio, et al.
Publicado: (2019)

Carfilzomib in Combination with Bortezomib Enhances Apoptotic Cell Death in B16-F1 Melanoma Cells
por: Lee, Min Seung, et al.
Publicado: (2021)

Neurons: The Interplay between Cytoskeleton, Ion Channels/Transporters and Mitochondria
por: Alberti, Paola, et al.
Publicado: (2022)

Health-related quality of life in the ENDEAVOR study: carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed/refractory multiple myeloma
por: Ludwig, Heinz, et al.
Publicado: (2019)

Impact of prior treatment on patients with relapsed multiple myeloma treated with carfilzomib and dexamethasone vs bortezomib and dexamethasone in the phase 3 ENDEAVOR study
por: Moreau, P, et al.
Publicado: (2017)

The cytotoxic activity of carfilzomib together with nelfinavir is superior to the bortezomib/nelfinavir combination in non-small cell lung carcinoma
por: Besse, Lenka, et al.
Publicado: (2023)

Bortezomib, lenalidomide and dexamethasone (VRd) vs carfilzomib, lenalidomide and dexamethasone (KRd) as induction therapy in newly diagnosed multiple myeloma
por: Tan, Carlyn Rose, et al.
Publicado: (2023)

Carfilzomib or bortezomib in combination with cyclophosphamide and dexamethasone followed by carfilzomib maintenance for patients with multiple myeloma after one prior therapy: results from a multicenter, phase II, randomized, controlled trial (MUKfive)
por: Yong, Kwee L., et al.
Publicado: (2021)

Bortezomib, Lenalidomide and Dexamethasone (VRd) vs Carfilzomib, Lenalidomide and Dexamethasone (KRd) as Induction Therapy in Newly Diagnosed Multiple Myeloma
por: Tan, Carlyn Rose, et al.
Publicado: (2023)

Proteasome inhibitors bortezomib and carfilzomib used for the treatment of multiple myeloma do not inhibit the serine protease HtrA2/Omi
por: Csizmadia, Vilmos, et al.
Publicado: (2016)

Inhibition of NHE1 transport activity and gene transcription in DRG neurons in oxaliplatin-induced painful peripheral neurotoxicity
por: Dionisi, Marianna, et al.
Publicado: (2023)

Effects of tubulin acetylation and tubulin acetyltransferase binding on microtubule structure
por: Howes, Stuart C., et al.
Publicado: (2014)

Calmangafodipir Reduces Sensory Alterations and Prevents Intraepidermal Nerve Fibers Loss in a Mouse Model of Oxaliplatin Induced Peripheral Neurotoxicity
por: Canta, Annalisa, et al.
Publicado: (2020)

Once weekly selinexor, carfilzomib and dexamethasone in carfilzomib non-refractory multiple myeloma patients
por: Gasparetto, Cristina, et al.
Publicado: (2021)

Efficacy and toxicity of carfilzomib- or bortezomib-based regimens for treatment of transplant-ineligible patients with newly diagnosed multiple myeloma: A meta-analysis
por: Xie, Chunhong, et al.
Publicado: (2022)

CR4056, a new analgesic I2 ligand, is highly effective against bortezomib-induced painful neuropathy in rats
por: Meregalli, Cristina, et al.
Publicado: (2012)

Bortezomib-induced neurotoxicity in human neurons is the consequence of nicotinamide adenine dinucleotide depletion
por: Snavely, Andrew R., et al.
Publicado: (2022)

Systems Pharmacology Modeling Identifies a Novel Treatment Strategy for Bortezomib-Induced Neuropathic Pain
por: Bloomingdale, Peter, et al.
Publicado: (2022)

HDACi: The Columbus’ Egg in Improving Cancer Treatment and Reducing Neurotoxicity?
por: Squarzoni, Angelica, et al.
Publicado: (2022)

Final analysis of carfilzomib, dexamethasone, and daratumumab vs carfilzomib and dexamethasone in the CANDOR study
por: Usmani, Saad Z., et al.
Publicado: (2023)

Human Intravenous Immunoglobulin Alleviates Neuropathic Symptoms in a Rat Model of Paclitaxel-Induced Peripheral Neurotoxicity
por: Meregalli, Cristina, et al.
Publicado: (2021)

Carfilzomib and the cardiorenal system in myeloma: an endothelial effect?
por: Rosenthal, A, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_qsekngtobgebbi42qg7qetnqtg